Polaris Partners — 2018 Investments

6 investments dated 2018 · listed companies and verified rows first · show all

Pulmatrixpulmatrix.comNASDAQ: PULMDec 2018SEC filingmedium confidence

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Board seatTerrance McGuire· per SEC Form D · $3.7M raise · filed Dec 2018

Co-investors5AM Ventures ALTITUDE LIFE SCIENCE VENTURES ARCH Venture Partners

KSQ Therapeuticsksqtx.com in 𝕏Sep 2018

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)

Board seatAlan Crane· per SEC Form D

Co-investorsAlpha Wave Global ARCH Venture Partners Flagship Pioneering LAV LG Technology Ventures Lilly Asia Ventures +3 more

Pandion Therapeuticspandiontx.comSeries A · Jan 2018 · $58Macquired by Merck · Feb 2021 · $1.9B

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seatAlan Crane· per SEC Form D

Co-investorsAccess Biotechnology JDRF T1D Fund Mission Biocapital RA Capital SR One Capital Management Versant Ventures

OM1om1.com inSeries B · May 2018 · $21M

OM1 develops AI-powered analytics and data infrastructure for healthcare organizations to measure patient outcomes, predict health trajectories, and accelerate medical research using real-world clinical data.

AI & Machine LearningData & InfrastructureHealthtechMedical DevicesBoston, US

Richard Gliklich, MD(Founder)Richard E. Gliklich(Executive Officer, Director)Richard Gliklich(Founder)

BoardRory O'Driscoll(Director)inLarry Bohn(Director)David Barrett(Director)

Co-investors7wire Ventures Breyer Capital Corewell Health Ventures General Catalyst M33 Growth Scale Venture Partners

Simon AIsimon.aiSeries B · Jul 2018 · $20M

Simon AI offers an agentic marketing platform for lifecycle marketers to plan and launch personalized campaigns through a conversational, goal-based AI workflow.

AI & Machine LearningMarketing TechSaaSNew York City, US

Jason Davis(Founder)

Co-investorsF-Prime Capital .406 Ventures

Simon Datasimondata.com inSeries B · Jul 2018 · $20MAcquired

Simon AI provides customer data and personalization tools to marketing teams for driving one-to-one customer messaging across touchpoints.

AI & Machine LearningData & InfrastructureMarketing TechSaaSBrooklyn, US

Jason Davis(Founder)inMatt Walker(Founder)inJoshua Neckes(Founder)

Co-investors.406 Ventures Commerce Ventures BoxGroup Eight Roads Ventures Slow Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.